The Chinese car company -- U.S. investor Warren Buffett's Berkshire Hathaway bought 9.9% of it in 2009 -- had said it would be selling cars here by 2010.
"Back then, we had passion, but we had no brand, no history, no capital and no competitive advantage," Bloomberg quoted said Stella Li, senior vice president in charge of the company's U.S. business, as saying during an interview at BYD's headquarters in Shenzhen in China's southern Guangdong province.
"BYD has become more fashionable and we have improved our design and safety. We don't want to compete on price anymore, but on quality and innovation," she told Bloomberg.
Top 5 Gas Stocks To Own Right Now: Stryker Corporation(SYK)
Stryker Corporation, together with its subsidiaries, operates as a medical technology company worldwide. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment offers orthopaedic reconstructive (hip and knee) and trauma implant systems, as well as other related products. The MedSurg segment provides surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; and other related products. The Neurotechnology and Spine segment offers neurovascular products, spinal implant systems, and other related products. The company sells its products through local dealers and direct sales force to doctors, hospitals, and other healthcare facilities, as well as through third-party dealers and distributors in the United States, Europe, the Middle East, Africa, and Japan, Canada, the Pacific region, and the Latin America region. Stryker Corporat ion was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Advisors' Opinion:- [By Alex Planes]
My Foolish colleague Dan Caplinger notes that the Obamacare has already had a huge impact on the U.S. health care industry, as companies face an additional 2.3% tax on medical devices. Hospitals have also faced substantial cuts in Medicare reimbursement and steeper penalties for failing to comply with certain readmission guidelines. As a result, hospitals have been hesitant to spend large amounts of cash on Intuitive's robot systems, which typically cost more than $1.5 million apiece. Hedge fund Lone Pine Capital recently sold its stake in Intuitive for $430 million, citing anemic sales growth of yjr da Vinci systems in the U. S. The new Obamacare restrictions have also forced fellow medical-device maker Stryker (NYSE: SYK ) to slash around 1,170 jobs, while Edwards Lifesciences�sold its Sapien heart valve segment to maintain its dominant position in the U.S markets.
- [By Seth Jayson]
Stryker (NYSE: SYK ) reported earnings on July 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Stryker met expectations on revenues and missed estimates on earnings per share. - [By Dan Caplinger]
The lower a company's profit margin, the greater the impact of the medical-device tax as a proportion of net income. For the highly profitable robotic surgical giant Intuitive Surgical (NASDAQ: ISRG ) , a medical-device tax of 2.3% equates to less than an 8% additional levy on net income from its da Vinci surgical systems using the same assumptions as above, thanks to the company's 30% profit margin. But for Stryker (NYSE: SYK ) , which has a profit margin of about 15%, the medical-device tax is equivalent to a greater than 15% surtax on income from medical devices.
Best Promising Stocks For 2014: Synaptics Inc (SYNA)
Synaptics Incorporated is a developer and supplier of custom-designed human interface solutions that enable people to interact with a range of mobile computing, communications, entertainment, and other electronic devices. The Company focuses on the personal computer ( PC) market, primarily notebook computers, including ultrabooks, the markets for digital lifestyle products, including mobile smartphones and feature phones, the tablet market, and other select electronic device markets with its customized human interface solutions. The Company generally supplies its human interface solutions to its original equipment manufacturer (OEM) customers through their contract manufacturers, which take delivery of its products and pay the Company directly for them.
The Company provides custom human interface solutions for navigation, cursor control, and multimedia controls for many of the world�� premier PC OEMs. In addition to notebook applications, other PC product applications for its technology include peripherals, such as keyboards, mice, and monitors, as well as remote control devices for desktops, PCs, and digital home applications. Its solutions for the PC market include the TouchPad, the ClickPad, the TouchStyk, and dual pointing solutions. The Company�� tablet includes the ClearPad Series 7. In August 2012, it acquired Pacinian and the Video Display Operation of Integrated Device Technology, Inc.
TouchPad
TouchPad provides a method for screen navigation, cursor movement, and gestures and provides a platform for interactive input for both the consumer and corporate markets. TouchPad solutions offer various advanced features, including Scrolling, Customizable tap zones, performance of entertainment, productivity, and media tasks, tapping and dragging of icons, and device Interaction. The Company�� TouchPad solutions are available in a variety of sizes, electrical interfaces, and thicknesses.
ClickPad
The Company�� ClickPad introduces! a clickable mechanical design to the TouchPad application. Its ClickPad is activated by pressing down on the internal tact switch to perform a left- or right-button click and provides feedback similar to pressing a physical button. The latest version of ClickPad features ClickEQ, which is a mechanical solution.
ForcePad
The Company's ForcePad is a thinner version of the Company's ClickPad, which introduces a new dimension in control through the addition of variable force sensitivity. ForcePad is designed to provide consistent performance across OEM models through its design intelligence and self-calibration features.
Dual Pointing Solutions
The dual pointing solutions offer a TouchPad with a pointing stick in a single notebook computer. Its dual pointing solutions also provide the end user the ability to use both interfaces interchangeably. The Company has developed two solutions for use in the dual pointing market. Its first solution integrates all the electronics for controlling a third-party resistive strain gauge pointing stick onto its TouchPad PCB. Its second dual pointing solution uses its TouchStyk and offers the OEM integration. The second solution is a completely modular design, allowing OEMs to offer TouchPad-only, TouchStyk-only, or dual pointing solutions on a build-to-order basis.
TouchStyk
The Company�� TouchStyk is a pointing stick interface solution for PC notebooks. TouchStyk is an integrated module that uses capacitive technology similar to that of its TouchPad. TouchStyk is enabled with press-to-select and tap-to-click capabilities and can be integrated into multiple computing and communications devices.
NavPoint
The Company�� NavPoint solution offers TouchPad functionality for small form factor devices in accessing and managing content in handheld devices through navigation controls. It also includes short- and long-distance scrolling features, tapping, and mouse-like cursor navigation.
ClearPadThe Company�� ClearPad touchscreen solutions consist of a transparent, thin capacitive sensor, which is a discrete sensor, that can be placed over any display, such as an liquid crystal display (LCD) or organic light-emitting diode (OLED). Its ClearPad Series 3 can provide full-time tracking of ten or more fingers simultaneously and features stylus support and support for various sensor configurations, including discrete sensors, sensor-on-lens, which includes sensor electrodes patterned on the bottom of the glass cover lens; on-cell, which includes sensor electrodes patterned on the display glass, and in-cell, which includes sensor electrodes patterned inside the LCD glass.
The Company�� ClearPad Series 4 products combines its capacitive multi-touch technology with a device�� display driver in a single-chip solution delivering advanced display noise management and capacitive sensing performance. Its ClearPad Series 7 products are designed for large touchscreen market for products more closely related to clamshell notebooks, slates, tablets, and similar devices. The Company�� ClearPad Series 7 products include single-chip touchscreen solutions and multi-chip touchscreen solutions designed for devices, such as gaming applications.
FlexPad
This capacitive sensing interface is mounted beneath a mechanical keypad, and allows the keypad surface to be used for advanced scrolling and navigation features, character entry, and advanced gesture input on handheld devices. With navigation functionality similar to a touch pad, FlexPad offers interface and industrial design differentiation.
ClearButtons
The Company�� ClearButtons product is an extension of its core capacitive sensing technology that has been used in TouchPad solutions for notebook PCs, mobile smartphones, and feature phones. ClearButtons is a sensor that can be mounted under plastic, providing OEMs with integration and design options for scrolling and b! uttons.
TouchButtons
The Company�� TouchButtons product provides capacitive button and scrolling controls for an interface solution designed to replace mechanical buttons. Button arrays and ScrollStrips can be programmed to perform various functions, such as controls for multimedia, display and device settings in notebook PCs, multimedia keyboards, MP3 players, digital photo frames, monitors, and other digital lifestyle products. TouchButton interfaces are designed for integration under the plastic face of a device, allowing for a sealed, durable, and thin design, which can be coupled with light emitting diode (LED) animation.
ThinTouchTM
The Company�� ThinTouch, is a design technology that delivers a full keyboard solution that is 40% thinner than traditional keyboard solutions. ThinTouch provides design architecture that facilitates backlighting.
Proximity Sensing
The Company�� proximity sensing technology enables users to interact with consumer electronics without touch. With this technology, sensors in a device, such as a notebook PC, mobile phone, peripheral, or digital photo frame, sense the presence of a user�� hand to activate a function, such as illuminating LEDs for discoverable buttons or waking devices from power-saving mode.
Dual Mode
The Company�� Dual Mode-enabled TouchPad interface allows a user to switch between cursor control and icon-based control on the TouchPad surface. In default mode, a Dual Mode-enabled TouchPad provides the same cursor control for on-screen navigation as a standard TouchPad. When the user taps on a launch icon located on the TouchPad surface, control icons illuminate on the TouchPad surface.
ChiralMotion Gesture
The Company�� ChiralMotion Gesture technology can be applied for continuous circular motion to initiate precise and fine-tuned scrolling on any two-dimensional input surface, such as its TouchPad and ClearPad solutions. ChiralMoti! on Gestur! e technology is suited for small handheld products, such as feature-rich mobile handsets, personal navigation systems, and personal media players that require easy access for entertainment, music, and other digital files.
Synaptics Gesture Suite
The Company�� Synaptics Gesture Suite (SGSTM) provides users with an intuitive way to interact with their notebook computers. SGS was developed by analyzing the most common workflows from entertainment activities, such as viewing photos and listening to music, to productivity activities, such as accessing e-mails and presentations. SGS represents a portfolio of gestures available on its interface solutions. These gestures are compatible with a range of Microsoft Windows and Linux applications. Gestures in the market include Pinch, Rotate, ChiralMotion Scrolling, Two-Finger Scrolling, Three-Finger Flick, Three-Finger Down, and Four-Finger Flick.
Enhanced Gesture Recognition
Synaptics�� Enhanced Gesture Recognition is a suite of ClearPad gestures included in its firmware. Customers can easily enable SingleTouch gestures, such as Tap, Double Tap, Press, and Flick; DualTouch gestures, such as Pinch and Pivot Rotate, and multi-finger gestures for ClearPad directly from its touch module firmware. No additional ssoftware is required on the host processor to implement these gestures.
Dual Mode for TouchPad
The Company's Dual Mode-enabled TouchPad interface allows a user to switch between cursor control and icon-based controls on the TouchPad surface. In default mode, a Dual Mode-enabled TouchPad provides the same cursor control for on-screen navigation as a standard TouchPad.
The Company competes with Alps Electric, Elan Microelectronics, Atmel, Cypress and Melfas.
Advisors' Opinion:- [By Evan Niu, CFA]
You got me there
In these specific use cases, Apple simply can't compete. Short of calling up Synaptics (NASDAQ: SYNA ) and incorporating the company's ClearPad technology and its 3D-Touch capabilities, the iPhone will never know when you're about to touch it. Apple used to tap Synaptics for iPod click-wheel sensors, but that was a long time ago. The Samsung design win has given Synaptics a nice pop, since the GS4 is bound to bring in abundant unit volumes.
Best Promising Stocks For 2014: Arca Biopharma Inc.(ABIO)
ARCA biopharma, Inc., a biopharmaceutical company, engages in the development of genetically-targeted therapies for cardiovascular diseases. Its principal product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure and also for the prevention of atrial fibrillation in patients with heart failure. The company has identified common genetic variations in the cardiovascular system that it believes interact with Gencaro?s pharmacology and may predict patient response. ARCA has collaboration with Laboratory Corporation of America to develop the Gencaro Test, a companion test for the genetic markers that identify these common genetic variations. The company is headquartered in Broomfield, Colorado.
Advisors' Opinion:- [By Roberto Pedone]
One biopharmaceuticals player that's starting to trend within range of triggering a major breakout trade is Arca Biopharma (ABIO), which is developing genetically-targeted therapies for cardiovascular diseases. This stock has been under pressure by the sellers so far in 2013, with shares down big by 37%.
If you take a look at the chart for Arca Biopharma, you'll notice that this stock has been trending sideways and consolidating for the last two months and change, with shares moving between $1.29 on the downside and $1.53 on the upside. Shares of ABIO are now starting to uptrend over the last month as the stock moves within range of triggering a major breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in ABIO if it manages to break out above some near-term overhead resistance levels at $1.47 to $1.53 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 331,253 shares. If that breakout triggers soon, then ABIO will set up to re-test or possibly take out its next major overhead resistance level at $1.65 a share. Any high-volume move above $1.65 will then give ABIO a chance to re-fill some of its previous gap down zone from May that started near $2.80 a share.
Traders can look to buy ABIO off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $1.38 a share, or near more support at $1.29 a share. One can also buy ABIO off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Bryan Murphy]
Ever notice how, on occasion, there's that stock idea that just won't go away, and keep moving back into your radar? They don't always work out, but sometimes, it turns out there was a very good reason that name kept surfacing as a trade candidate. For me (right now anyway), Arca Biopharma Inc. (NASDAQ:ABIO) that nagging stock that just keeps coming back on my plate. I talked about ABIO on October 7th and again on October 21st, both times bullishly, and though the stock's gone nowhere since then, I find myself liking Arca Biopharma enough to once again suggest there's a breakout brewing here.
- [By James E. Brumley]
Traders may not want to get married for the long haul to any of them, but for speculators looking for a quick, profitable hit, Arca Biopharma Inc. (NASDAQ:ABIO), Pluristem Therapeutics Inc. (NASDAQ:PSTI), and Bacterin International Holdings Inc. (NYSEMKT:BONE) may be better-than-average bets. Here's why.
- [By Bryan Murphy]
Congratulations if you were in a GW Pharmaceuticals PLC (NASDAQ:GWPH) position anytime before today's open. Now get out. Not only is the party over for GWPH, there's something better you could do with your money now. It's a not-so-obscure-any-longer biotech called Arca Biopharma Inc. (NASDAQ:ABIO), and though the stock's up pretty nicely since two Fridays ago, ABIO is also just getting started.
Best Promising Stocks For 2014: Walter Investment Management Corp (WAC)
Walter Investment Management Corp., together with its subsidiaries, is a fee-based business services provider to the residential mortgage industry. The Company is a specialty servicer providing residential loan servicing that focuses on credit-sensitive residential mortgage assets located in the United States. It is also a mortgage portfolio owner and operates an insurance agency serving residential loan customers. The Company operates in four segments: Servicing, Asset Receivables Management (ARM), Insurance, and Loans and Residuals. On July 1, 2011, the Company acquired GTCS Holdings LLC. In November 2012, the Company acquired Reverse Mortgage Solutions, Inc. In January 2013, it acquired originations and capital markets platform of Residential Capital, LLC. In April 2013, the Company announced that its wholly owned subsidiary Reverse Mortgage Solutions, Inc. (RMS) acquired a (Wells Fargo).
Servicing
The Company�� Servicing business segment consists of operations that perform servicing for third-party investors in residential mortgages, manufactured housing and consumer installment loans and contracts, as well as for the Loans and Residuals segment and for the Non-Residual Trusts. During the year ended December 31, 2011, the Company added 259,000 account.
ARM
The Company�� ARM business performs collections of delinquent balances on loans.
Insurance
The Company�� Insurance segment consists of its agency business and its reinsurance businesses. The Company�� Insurance business segment provides voluntary and lender-placed hazard insurance for residential loans, as well as other ancillary products.
Loans and Residuals
The Company's Loans and Residuals business segment consists of the assets and liabilities of the Residual Trusts. It also includes its unencumbered residential loan portfolio and real estate owned.
Advisors' Opinion:- [By Holly LaFon]
Despite economic and political turmoil, equity markets performed well across the board in September of 2013 and over the trailing twelve months. The September gains reversed losses in August and also resulted in positive overall quarterly performance with a number of major indexes moving further into record territory. After disturbing the markets in May and June with comments that they may taper Quantitative Easing (QE), the Fed surprised investors with an announcement that it would not reduce its asset purchases in the near-term. The announcement removed fears that a continued rise in interest rates may stall the economic recovery, as seen by the market's negative reaction to the sharp rise in the 10-year Treasury rate in August of 2013. Investors were also comforted by improving fundamentals both domestically and abroad. The Eurozone may finally be emerging from its prolonged recession and a number of economic reports in the U.S. continue to show progress. Specifically, initial unemployment claims dropped to a multiyear low early in September and the housing market continued to improve, as evidenced by prices rising 12.4 percent year-over year, which along with the stock market's strength, has created a positive wealth effect for consumers. In response to this general economic improvement, consumer confidence increased at the end of September, and the index of leading economic indicators ticked up as well, suggesting that, absent the effects of politics, the recovery in the real economy was continuing. Our portfolios that focus on corporate restructuring (Keeley Small Cap Value, Keeley Small-Mid Cap Value, Keeley Mid Cap Value, Keeley All Cap Value, and Keeley Alternative Value) have all experienced a productive investment cycle with respect to their opportunity sets, and many of our holdings have posted impressive results in recent quarters. Although we acknowledge an improving economy has boosted the outlook for our more cyclical holdings, our research has gu
- [By Amanda Alix]
An immensely profitable enterprise
With a line-up of willing sellers -- and free of the capital constraints of banks -- mortgage servicers like Nationstar Mortgage (NYSE: NSM ) , Ocwen Financial (NYSE: OCN ) , and Walter Investment (NYSE: WAC ) have seen their stars rise quickly, experiencing stock price surges of at least 100% over the past year. - [By Christina Rexrode]
Companies like Nationstar have grown tremendously in recent years by buying the rights to service mortgages from big banks. Ben Chittenden, an analyst at Oppenheimer & Co., estimates that Nationstar, Ocwen Financial Corp. (OCN) and Walter Investment Management (WAC) have grown their combined servicing books from $141 billion in the first quarter of 2011 to $1 trillion in the third quarter of 2013.
- [By Sean Williams]
What: Shares of Walter Investment Management (NYSE: WAC ) , a residential mortgage services provider, jumped as much as 12% after the Federal Housing Finance Agency extended the HARP program for two additional years.
Best Promising Stocks For 2014: NPS Pharmaceuticals Inc.(NPSP)
NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company?s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.
Advisors' Opinion:- [By Ben Levisohn]
Markey rates the stock a Buy with an $11 price target. Shares of MannKind have jumped 14% to $7.85 today. The SPDR Biotech ETF (XBI) has gained 0.7% to $119.85 today, while Alnylam Pharmaceuticals (ALNY) has gained 1% to $49.05, NPS Pharmaceuticals (NPSP) has fallen 4.1% to $23.56, and InterMune (ITMN) has risen 2.6% to $14.89.
- [By RichardCox]
Investing in biotech can seem intimidating, given the complex nature of the industry. So, for those looking for a simple way to gain exposure to the industry, a basket sector ETF might be the best choice. The clearest option here is the SPDR S&P Biotech ETF (XBI), which has nominal gross expense ratio of 0.35% and an average return of nearly 10% since it was started in 2006. The fund's holdings include Sarepta Therapeutics (SRPT), which has made well-documented progress in Eteplirsen, its Duchenne muscular dystrophy drug. Most analysts expect Eteplirsen to receive relatively quick FDA approval, helping support the underlying value of the stock. Other holdings include NPS Pharmaceuticals (NPSP), which recently bought back the right to Gattex, a short bowel syndrome drug.
Best Promising Stocks For 2014: BanColombia S.A. (CIB)
Bancolombia S.A., a full service financial institution, provides various banking products and services to individual and corporate customers in Colombia, as well as in Panama, El Salvador, Puerto Rico, the Cayman Islands, Peru, Brazil, the United States, and Spain. The company offers savings and checking accounts, fixed term deposits, and investment products; and trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal loans, vehicle loans, payroll loans, and overdrafts. It also provides mortgage banking, factoring, treasury, cash management, foreign currency, and bancassurance and insurance; and asset management and trust services that comprise money market accounts, mutual and pension funds, private equity funds, payment trust, custody services, and corporate trust. In addition, the company offers brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign cu rrencies, fixed income securities, mutual funds, and structured products; and investment banking services, including advising and assisting companies from various economic sectors in project finance, capital markets, capital investments, mergers and acquisitions, restructurings, and corporate lending. Further, it provides financial and operational leases, including cross-border and international leasing services; and pension plan administration services. The company offers its services through a traditional branch network, and sales and customer representatives, as well as through mobile branches, non-banking correspondents, an ATM network, online and computer banking, telephone and mobile phone banking, and electronic funds transfer at point of sale (PACs). As of September 30, 2012, it had 978 branches and 3,703 ATMs. Bancolombia S.A. was founded in 1945 and is headquartered in Medellin, Colombia.
Advisors' Opinion:- [By Lisa Levin]
Bancolombia SA (NYSE: CIB) shares touched a new 52-week low of $47.94. Bancolombia's trailing-twelve-month ROA is 1.45%.
Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets
- [By Matt Smith]
Bancolombia appears attractively priced
Another Colombian company that appears under-valued is the Andean country's largest commercial bank Bancolombia (NYSE: CIB ) . For the year-to-date Bancolombia's share price fell 17% because of a weak second quarter bottom-line. This decline was primarily caused by the bank's net income plunging by 41% year-over-year because of mark-to-market losses caused by the value lost in the bank's securities portfolio.
No comments:
Post a Comment